CompletedNCT04027361
Extended-Release Amphetamine and Driving in Young Adults With ADHD
About this title
Read the official source — NCT04027361Medication studyAges 18–25United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 25 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 1, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- Tris Pharma, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 25 Years
- Official registry ID
- NCT04027361
- Official title
Show the full official title
Driving Performance in Patients Aged 18 to 25 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) After a Single-Dose of Amphetamine Extended-Release Tablets: A Pilot, Double-Blind, Placebo-Controlled Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBoston
Questions about this study
Who is behind this study?
The study sponsor is Tris Pharma, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Amphetamine Extended Release (ER) Tablet 20 mg.
Who was this study for?
Listed age limits: 18 years to 25 years.
